|
Jennifer Ligibel, MD (Dana-Farber Cancer Institute) will present results from Alliance A011401/BWEL (Randomized phase III trial evaluating the role of weight loss
in adjuvant treatment of overweight and obese women with early breast cancer). BWEL is a phase III randomized controlled trial evaluating the impact of a weight loss intervention on disease recurrence and other endpoints in overweight and obese women with stage II-III breast cancer. Dr. Ligibel is a Vice-Chair of the Alliance Prevention Committee.
1817MO - Mini oral session: Supportive and palliative care, Sunday, September 15, 3:15 am CT (10:15 CEST)
|